ArticleMolecular therapy : the journal of the American Society of Gene Therapy2022
Optogenetic therapy restores retinal activity in primate for at least a year following photoreceptor ablation.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Automated montaging and contrast stretching of adaptive optics ophthalmoscope images.Biomedical optics express · 2026Article
- Refractive adaptive optics scanning light ophthalmoscope with fast 2D MEMS scanner.Biomedical optics express · 2026Article
- Automated animal gimbal steering for retinal imaging and stimulation.Biomedical optics express · 2026Article
- Inner Limiting Membrane Peel Extends In Vivo Calcium Imaging of Retinal Ganglion Cell Activity Beyond the Fovea in Non-Human Primate.Investigative ophthalmology & visual science · 2025Article
- Evolution of Light-Sensitive Proteins in Optogenetic Approaches for Vision Restoration: A Comprehensive Review.Biomedicines · 2025Review
- In Vivo Visualization of Intravascular Patrolling Immune Cells in the Primate Eye.Investigative ophthalmology & visual science · 2024Article
- Foveal RGCs develop altered calcium dynamics weeks after photoreceptor ablation.bioRxiv : the preprint server for biology · 2024Article
- Deprivation of visual input alters specific subset of inhibitory neurons and affect thalamic afferent terminals in V1 ofFrontiers in cellular neuroscience · 2024Article
- Current approaches to vision restoration using optogenetic therapy.Frontiers in cellular neuroscience · 2023Review
- Optogenetic Therapy for Visual Restoration.International journal of molecular sciences · 2022Review
- Applications and challenges of rhodopsin-based optogenetics in biomedicine.Frontiers in neuroscience · 2022Review
- Stage-Dependent Changes of Visual Function and Electrical Response of the Retina in theFrontiers in cellular neuroscience · 2022Article
- Foveal Retinal Ganglion Cells Develop Altered Calcium Dynamics Weeks After Photoreceptor Ablation.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
All retina-based vision restoration approaches rely on the assumption that photoreceptor loss does not preclude reactivation of the remaining retinal architecture. Whether extended periods of vision loss limit the efficacy of restorative therapies at the retinal level is unknown. We examined long-term changes in optogenetic responsivity of foveal retinal ganglion cells (RGCs) in non-human primates following localized photoreceptor ablation by high-intensity laser exposure. By performing fluorescence adaptive optics scanning light ophthalmoscopy (AOSLO) of RGCs expressing both the calcium indicator GCaMP6s and the optogenetic actuator ChrimsonR, it was possible to track optogenetic-mediated calcium responses in deafferented RGCs over time. Fluorescence fundus photography revealed a 40% reduction in ChrimsonR fluorescence from RGCs lacking photoreceptor input over the 3 weeks following photoreceptor ablation. Despite this, in vivo imaging revealed good cellular preservation of RGCs 3 months after the loss of photoreceptor input, and histology confirmed good structural preservation at 2 years. Optogenetic responses of RGCs in primate persisted for at least 1 year after the loss of photoreceptor input, with a sensitivity index similar to optogenetic responses recorded in intact retina. These results are promising for all potential therapeutic approaches to vision restoration that rely on preservation and reactivation of RGCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.